Buy Plavix (Clopidogrel) at reputable online pharmacy and save extra money! No prescription! No hidden fees!
Plavix, one of the few anti-clotting drugs on the market at present, could make a big hit to its $ 8.5 billion sales rate as the result of two recent revelations which are resulting in the FDA reviewing the drug’s labeling. It is strongly believed it is inevitable that the FDA will impose a more restrictive label which will substantially reduce the use of Plavix by as much as 30%.
The losers: This drug is prescribed to prevent blood clots and as the second most prescribed drug in the world, Plavix is widely prescribed for patients that have experienced heart attack, stroke, or other vascular events and who are believed to be a high risk for a recurrent event caused by a blood clot. But 30% of patients using this drug do not metabolize the drug because of genetic variation thus receiving little or not benefit.
The winners: The winners are those multinational companies that will benefit from providing million of PCR based tests mandated by the FDA to detect the genetic variations that renders Plavix ineffective. We strongly believed Roche Molecular Diagnostics and indirectly Affymetrix which supplies the test to Roche will be the major beneficiary of the label change but other PCR companies will also benefit.
New England Journal of Medicine issued two studies that strongly suggest that data from patients taking Plavix over a number of years found that individual with a particular gene variation had higher rates of heart attack, other cardiac-related events and death. The gene variant appears to lessen the function of an enzyme needed to activate the medicine. A third study in British Journal Lancet found out that in patients under the age of 40 who had a history of heart attack, the risk of having a new heart attack or death was three times greater for those with the gene version. Two of the studies also suggested that the drug was less effective in about 30 % of the population that has the mutated gene from one parent, while one study indicated that the drug is less effective in the 5 % of the entire population that has the gene from both parents.